Skip Navigation

Europace 2005 7(5):492-499; doi:10.1016/j.eupc.2005.05.012
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Scholten, M. F.
Right arrow Articles by Jordaens, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scholten, M. F.
Right arrow Articles by Jordaens, L. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.

REVIEW ARTICLE

Anticoagulation in atrial fibrillation and flutter

M. F. Scholtena,*, A. S. Thorntona, J. M. Mekela, P. J. Koudstaalb and L. J. Jordaensa

aDepartment of Clinical Electrophysiology, Thoraxcentre, Erasmus University Medical Centre Dr Molewaterplein 40, 3015 GM, Rotterdam, The Netherlands; bDepartment of Neurology, Erasmus University Medical Centre Dr Molewaterplein 40, 3015 GM, Rotterdam, The Netherlands

Atrial fibrillation and atrial flutter are important risk factors for stroke. Based on a literature search, pathogenesis of thromboembolism, risk assessment in patients, efficacy of anticoagulation therapy and its alternatives are discussed. Special emphasis is put on issues like paroxysmal atrial fibrillation, atrial flutter and anticoagulation surrounding catheter ablation and cardioversion. A strategy for anticoagulation around the time of pulmonary vein ablation is suggested.

Key Words: atrial fibrillation, anticoagulation, catheterablation

*Corresponding author. Tel.: +31 10 463 3991; fax: +31 10 463 4420. E-mail address: m.f.scholten{at}erasmusmc.nl (M.F. Scholten)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mayo Clin Proc.Home page
D. W. C. Ng, G. T. Altemose, Q. Wu, K. Srivathsan, and L. R. P. Scott
Typical Atrial Flutter as a Risk Factor for the Development of Atrial Fibrillation in Patients Without Otherwise Demonstrable Atrial Tachyarrhythmias
Mayo Clin. Proc., June 1, 2008; 83(6): 646 - 650.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Nieuwlaat, A. Capucci, G. Y.H. Lip, S. B. Olsson, M. H. Prins, F. H. Nieman, J. Lopez-Sendon, P. E. Vardas, E. Aliot, M. Santini, et al.
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation
Eur. Heart J., December 2, 2006; 27(24): 3018 - 3026.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.